Strong Q2 revenue growth of 288% YoY, IM8 achieving sixth consecutive record quarter with 359% YoY growth, first month of positive consolidated Adjusted Free Cash Flow, raised FY 2026 guidance, introduced FY 2027 guidance exceeding $400 million, and significant insider buying by CEO and CFO demonstrate strong business momentum and management confidence in future performance.
Company demonstrated exceptional growth trajectory with IM8 becoming fastest-growing premium supplement brand ever, raised revenue guidance twice in 2026, secured $1 billion non-dilutive financing, achieved strong unit economics ($1.44 gross profit per $1 acquisition spend), and maintains financial strength with $139.7 million in cash and assets. The financing structure preserves shareholder value without equity dilution.
The partnership expands IM8's market reach and creates a differentiated value proposition by combining supplements with measurable health outcomes. The company is achieving strong growth metrics ($100M+ annualized recurring revenue within 11 months) and the partnership addresses a key market gap, positioning IM8 competitively in the wellness industry.
Articles that tag PRENW but are mainly about other companies.
Listed among key industry players investing in biomarker testing and consumer-focused subscription models in a high-growth market with strong tailwinds from digital health adoption.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
